Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkins Lymphoma
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2019
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Antithymocyte globulin; Ciclosporin; Ciclosporin; Mycophenolate mofetil; Mycophenolate mofetil; Rituximab
- Indications Graft-versus-host disease; Non-Hodgkin's lymphoma
- Focus Biomarker; Therapeutic Use
- 20 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.
- 20 Mar 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Jan 2020.
- 02 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.